Medpace Stock Gets Another IBD Composite Rating Upgrade

Medpace (MEDP) saw its IBD SmartSelect Composite Rating jump to 96 Wednesday, up from 91 the day before.


The new score indicates Medpace stock is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. The best stocks tend to have a 95 or better grade as they begin to launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.

Medpace stock is now out of buy range after gapping up, after earnings, from a 185.19 buy point in a flat base.

Looking For The Best Stocks To Buy And Watch? Start Here


Medplace stock earns a 95 EPS Rating, meaning its recent quarterly and annual earnings growth tops 95% of all stocks.

Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.

In Q3, the company reported 18% EPS growth. Revenue growth came in at 28%, down from 36% in the previous quarter.

Medpace stock holds the No. 4 rank among its peers in the Medical-Research Equipment/Services industry group. Charles River Labs International (CRL) is the top-ranked stock within the group.


Which Companies Are Now Outperforming 95% Of All Stocks?

See Which Stocks Just Came On — And Off — IBD’s Top Stock Lists

Evaluate Any Stock With Stock Ratings, IBD Charts And Stock Checkup

Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button